Form D · Biotechnology
Paragon Bioservices, Inc.
Baltimore, MD · CIK 0001623394
Offering snapshot reported Aug 6, 2018 · SEC filing
- Reported sold
- $5M Offering amount: $5M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $10.4K Reported outside-investor minimum
- First sale
- Aug 3, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 6, 2018 | Initial | $5,000,000 | No comparison | 9 | SEC filing |
| May 26, 2017 | Initial | $2,400,000 | No comparison | 9 | SEC filing |
| Aug 18, 2015 | Initial | $2,000,000 | No comparison | 7 | SEC filing |
| Nov 4, 2014 | Initial | $13,500,000 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-318531
Source: Form D, filed Aug 6, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Peter Buzy | Director, Executive |
| Marco Chacon | Director |
| Patrick Hervy | Director |
| Donald Hughes | Director |
| Christopher Kersey | Director |
| Kapila Ratnam | Director |
| Robert Roche | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
801 W. Baltimore Street Suite 401
Baltimore, MD, 21201
Baltimore, MD, 21201